OBJECTIVE: To determine the direct medical costs of type 1 diabetes mellitus (T1DM) to the National Brazilian Health-Care System (NBHCS) and quantify the contribution of each individual component to the total cost. METHODS: A retrospective, cross-sectional, nationwide multicentre study was conducted between 2008 and 2010 in 28 public clinics in 20 Brazilian cities. The study included 3180 patients with T1DM (mean age 22 years ± 11.8) who were surveyed while receiving health care from the NBHCS. The mean duration of their diabetes was 10.3 years (± 8.0). The costs of tests and medical procedures, insulin pumps, and supplies for administration, and supplies for self-monitoring of blood glucose (SMBG) were obtained from national and local health system sources for 2010-2011. Annual direct medical costs were derived by adding the costs of medications, supplies, tests, medical consultations, procedures and hospitalizations over the year preceding the interview. FINDINGS: The average annual direct medical cost per capita was 1319.15 United States dollars (US$). Treatment-related expenditure - US$ 1216.33 per patient per year - represented 92.20% of total direct medical costs. Insulin administration supplies and SMBG (US$ 696.78 per patient per year) accounted for 52.82% of these total costs. Together, medical procedures and haemodialysis accounted for 5.73% (US$ 75.64 per patient per year) of direct medical costs. Consultations accounted for 1.94% of direct medical costs (US$ 25.62 per patient per year). CONCLUSION: Health technologies accounted for most direct medical costs of T1DM. These data can serve to reassess the distribution of resources for managing T1DM in Brazil's public health-care system.
OBJECTIVE: To determine the direct medical costs of type 1 diabetes mellitus (T1DM) to the National Brazilian Health-Care System (NBHCS) and quantify the contribution of each individual component to the total cost. METHODS: A retrospective, cross-sectional, nationwide multicentre study was conducted between 2008 and 2010 in 28 public clinics in 20 Brazilian cities. The study included 3180 patients with T1DM (mean age 22 years ± 11.8) who were surveyed while receiving health care from the NBHCS. The mean duration of their diabetes was 10.3 years (± 8.0). The costs of tests and medical procedures, insulin pumps, and supplies for administration, and supplies for self-monitoring of blood glucose (SMBG) were obtained from national and local health system sources for 2010-2011. Annual direct medical costs were derived by adding the costs of medications, supplies, tests, medical consultations, procedures and hospitalizations over the year preceding the interview. FINDINGS: The average annual direct medical cost per capita was 1319.15 United States dollars (US$). Treatment-related expenditure - US$ 1216.33 per patient per year - represented 92.20% of total direct medical costs. Insulin administration supplies and SMBG (US$ 696.78 per patient per year) accounted for 52.82% of these total costs. Together, medical procedures and haemodialysis accounted for 5.73% (US$ 75.64 per patient per year) of direct medical costs. Consultations accounted for 1.94% of direct medical costs (US$ 25.62 per patient per year). CONCLUSION: Health technologies accounted for most direct medical costs of T1DM. These data can serve to reassess the distribution of resources for managing T1DM in Brazil's public health-care system.
Authors: Marilia B Gomes; Alessandra Saldanha de Mattos Matheus; Luis Eduardo Calliari; Jorge Luiz Luescher; Thais Della Manna; Roberta Diaz Savoldelli; Roberta A Cobas; Wellington Siqueira Coelho; Balduino Tschiedel; Alberto José Ramos; Reine Marie Fonseca; Neuza Braga C Araujo; Henriqueta Guido Almeida; Naira Horta Melo; Debora Laredo Jezini; Carlos Antonio Negrato Journal: Acta Diabetol Date: 2012-06-12 Impact factor: 4.280
Authors: Marilia B Gomes; Marisa Coral; Roberta A Cobas; Sergio Atala Dib; Luis Henrique Canani; Márcia Nery; Maria Cristina Foss de Freitas; Manuel Faria; João Soares Felício; Saulo Cavalcanti da Silva; Hermelinda Pedrosa; Adriana Costa e Forti; Rosangela Roginski Rea; Antonio Carlos Pires; Renan Montenegro Junior; José Egídio Oliveira; Nelson Rassi; Carlos Antonio Negrato Journal: Diabetes Res Clin Pract Date: 2012-03-06 Impact factor: 5.602
Authors: L Govan; O Wu; A Briggs; H M Colhoun; J A McKnight; A D Morris; D W M Pearson; J R Petrie; N Sattar; S H Wild; R S Lindsay Journal: Diabetologia Date: 2011-05-24 Impact factor: 10.122
Authors: S P Laing; A J Swerdlow; S D Slater; A C Burden; A Morris; N R Waugh; W Gatling; P J Bingley; C C Patterson Journal: Diabetologia Date: 2003-05-28 Impact factor: 10.122
Authors: Marilia Brito Gomes; Carlos Antonio Negrato; Roberta Cobas; Lucianne Righeti Monteiro Tannus; Paolla Ribeiro Gonçalves; Pedro Carlos Barreto da Silva; João Regis Ivar Carneiro; Alessandra Saldanha Mattos Matheus; Sergio Atala Dib; Mirela Jobim Azevedo; Márcia Nery; Melanie Rodacki; Lenita Zajdenverg; Renan Magalhães Montenegro Junior; Janice Sepulveda; Luis Eduardo Calliari; Deborah Jezini; Neuza Braga; Jorge L Luescher; Renata S Berardo; Maria Carmo Arruda-Marques; Renata M Noronha; Thais D Manna; Roberta Salvodelli; Fernanda G Penha; Milton C Foss; Maria C Foss-Freitas; Antonio C Pires; Fernando C Robles; Maria de Fátima S Guedes; Patricia Dualib; Saulo C Silva; Emerson Sampaio; Rosangela Rea; Ana Cristina R Faria; Balduino Tschiedel; Suzana Lavigne; Luis Henrique Canani; Alessandra T Zucatti; Marisa Helena C Coral; Daniela Aline Pereira; Luiz Antonio Araujo; Monica Tolentino; Hermelinda C Pedrosa; Flaviane A Prado; Nelson Rassi; Leticia B Araujo; Reine Marie C Fonseca; Alexis D Guedes; Odelissa S Matos; Catia C Palma; Rossana Azulay; Adriana C Forti; Cristina Façanha; Ana Paula Montenegro; Naira H Melo; Karla F Rezende; Alberto Ramos; João Soares Felicio; Flavia M Santos Journal: Diabetol Metab Syndr Date: 2014-05-31 Impact factor: 3.320
Authors: Elizabeth D Brouwer; David Watkins; Zachary Olson; Jane Goett; Rachel Nugent; Carol Levin Journal: BMC Public Health Date: 2015-11-26 Impact factor: 3.295